Advanced search
Publication Cover
Emerging Microbes & Infections Volume 3, 2014 - Issue 1
Submit an article Journal homepage
1,312
Views
39
CrossRef citations to date
0
Altmetric
Original Articles

The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo

Peijun RenUnit of Anti-infective Research, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China;Université Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, 75013, Paris, France;Institut National de la Santé et de la Recherche Médicale, U1108 & Viral Pathogenesis Unit, Department of Virology, Institut Pasteur, 75724 Paris, France
,
Gang ZouUnit of Anti-infective Research, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
,
Benjamin BaillyUnit of Anti-infective Research, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China;Institute for Glycomics, Gold Coast Campus, Griffith University, 4222 Queensland, Australia
,
Shanshan XuUnit of Anti-infective Research, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
,
Mei ZengDepartment of Infectious Diseases, Children's Hospital of Fudan University, Shanghai 201102, China
,
Xinsheng Chen State Key Laboratory of Lead Compound Research, WuXi AppTec, Co., Ltd, Shanghai 200131, China
,
Liang Shen State Key Laboratory of Lead Compound Research, WuXi AppTec, Co., Ltd, Shanghai 200131, China
,
Ying ZhangInstitute of Medical Biology, Chinese Academy of Medicine Science, Kunming 650118, Yunnan Province, China
,
Patrice GuillonInstitute for Glycomics, Gold Coast Campus, Griffith University, 4222 Queensland, Australia
,
Fernando Arenzana-SeisdedosInstitut National de la Santé et de la Recherche Médicale, U1108 & Viral Pathogenesis Unit, Department of Virology, Institut Pasteur, 75724 Paris, France
,
Philippe BuchyVirology Unit, Institut Pasteur in Cambodia, 12201 Phnom Penh, Cambodia
,
Jian Li State Key Laboratory of Lead Compound Research, WuXi AppTec, Co., Ltd, Shanghai 200131, China
,
Mark von ItzsteinInstitute for Glycomics, Gold Coast Campus, Griffith University, 4222 Queensland, Australia
,
Qihan LiInstitute of Medical Biology, Chinese Academy of Medicine Science, Kunming 650118, Yunnan Province, China
&
Ralf AltmeyerUnit of Anti-infective Research, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, ChinaCorrespondence[email protected]
 show all
Pages 1-9 | Received 23 Sep 2015, Accepted 02 Nov 2015, Published online: 25 Jan 2019

  • Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH.Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis2010;10: 778–790.
  • Wang SM, Liu CC.Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther2009;7: 735–742.
  • World Health Organization. Hand, foot and mouth disease (HFMD).WHO: Manila, 2013.Available at http://www.wpro.who.int/emerging_diseases/HFMD/en/.
  • Yang F, Ren L, Xiong Z et al.Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol2009;47: 2351–2352.
  • Mirand A, Schuffenecker I, Henquell C et al.Phylogenetic evidence for a recent spread of two populations of human enterovirus 71 in European countries. J Gen Virol2010;91: 2263–2277.
  • Zeng M, Pu D, Mo X et al.Children of rural-to-urban migrant workers in China are at a higher risk of contracting severe hand, foot and mouth disease and EV71 infection: a hospital-based study. Emerg Microbes Infect2013;2: e72.
  • Xing W, Liao Q, Viboud CC et al.Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis2014;14: 308–318.
  • Zeng M, El Khatib NF, Tu S et al.Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J Clin Virol2012;53: 285–289.
  • Bessaud M, Razafindratsimandresy R, Nougairède A et al.Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human Enterovirus 71 isolates reveal a wide genetic diversity. PLoS ONE2014;9: e90624.
  • Khanh TH, Sabanathan S, Thanh TT et al.Enterovirus 71-associated hand, foot, and mouth disease, Southern Vietnam, 2011. Emerg Infect Dis2012;18: 2002–2005.
  • Yamayoshi S, Yamashita Y, Li J et al.Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med2009;15: 798–801.
  • Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu H.Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med2009;15: 794–797.
  • Yamayoshi S, Ohka S, Fujii K, Koike S.Functional comparison of SCARB2 and PSGL1 as receptors for enterovirus 71. J Virol2013;87: 3335–3347.
  • Tan CW, Poh CL, Sam IC, Chan YF.Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol2013;87: 611–620.
  • Du N, Cong H, Tian H et al.Cell surface vimentin is an attachment receptor for enterovirus 71. J Virol2014;88: 5816–5833.
  • Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T.Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol2010;9: 1097–1105.
  • Plevka P, Perera R, Yap ML, Cardosa J, Kuhn RJ, Rossmann MG.Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci USA2013;110: 5463–5467.
  • de Palma AM, Vliegen I, de Clercq E, Neyts J.Selective inhibitors of picornavirus replication. Med Res Rev2008;28: 823–884.
  • Zhang X, Song Z, Qin B et al.Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res2013;97: 264–269.
  • Lu G, Qi J, Chen Z et al.Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol2011;85: 10319–10331.
  • Zhang G, Zhou F, Gu B et al.In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol2012;157: 669–679.
  • Pourianfar HR, Poh CL, Fecondo J, Grollo L.In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. Virus Res2012;169: 22–29.
  • Yorke W.The treatment of Kala-Azar by “Bayer 205”. Br Med J1923;1: 370.
  • Faust SN, Woodrow CJ, Patel S et al.Sleeping sickness in brothers in london. Pediatr Infect Dis J2004;23: 879–881.
  • Lam ET, Au JL, Otterson GA et al.Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol2010;66: 1019–1029.
  • Jentsch KD, Hunsmann G, Hartmann H, Nickel P.Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds. J Gen Virol1987;68: 2183–2192.
  • Offensperger WB, Offensperger S, Walter E, Blum HE, Gerok W.Suramin prevents duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother1993;37: 1539–1542.
  • Xu W, Liu CF, Yan L et al.Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J2012;9: 8.
  • Liu J, Yang Y, Xu Y, Ma C, Qin C, Zhang L.Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J2011;8: 483.
  • Zhang Y, Cui W, Liu L et al.Pathogenesis study of enterovirus 71 infection in rhesus monkeys. Lab Invest2011;91: 1337–1350.
  • Liu L, Zhang Y, Wang J et al.Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One2013;8: e54451.
  • Haselhorst T, Garcia JM, Islam T et al.Avian influenza H5-containing virus-like particles (VLPs): host-cell receptor specificity by STD NMR spectroscopy. Angew Chem Int Ed Engl2008;47: 1910–1912.
  • Haselhorst T, Fleming FE, Dyason JC et al.Sialic acid dependence in rotavirus host cell invasion. Nat Chem Biol2009;5: 91–93.
  • Nagata N, Iwasaki T, Ami Y et al.Differential localization of neurons susceptible to enterovirus 71 and poliovirus type 1 in the central nervous system of cynomolgus monkeys after intravenous inoculation. J Gen Virol2004;85: 2981–2989.
  • Liu L, Zhao H, Zhang Y et al.Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology2011;412: 91–100.
  • Vanchieri C, Butler AS, Knutsen A. Addressing the barriers to pediatric drug development: workshop summary.Washington, DC: The National Academies Press, 2008.
  • Chong CR, Sullivan DJ Jr.New uses for old drugs. Nature2007;448: 645–646.
  • Kappagoda S, Singh U, Blackburn BG.Antiparasitic therapy. Mayo Clin Proc2011;86: 561–583.
  • Khaw M, Panosian CB.Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev1995;8: 427–439.
  • Kaur M, Reed E, Sartor O, Dahut W, Figg WD.Suramin's development: what did we learn? Invest New Drugs2002;20: 209–219.
  • Scher HI, Jodrell DI, Iversen JM et al.Use of adaptive control with feedback to individualize suramin dosing. Cancer Res1992;52: 64–70.
  • Bowden CJ, Figg WD, Dawson NA et al.A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol1996;39: 1–8.
  • Lustberg MB, Pant S, Ruppert AS et al.Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol2012;70: 49–56.
  • Nagata N, Shimizu H, Ami Y et al.Pyramidal and extrapyramidal involvement in experimental infection of cynomolgus monkeys with enterovirus 71. J Med Virol2002;67: 207–216.
  • Altmeyer R.Virus attachment and entry offer numerous targets for antiviral therapy. Curr Pharm Des2004;10: 3701–3712.
  • Vercauteren K, Leroux-Roels G, Meuleman P.Blocking HCV entry as potential antiviral therapy. Future Virol2012;7: 547–561.
  • Curreli F, Choudhury S, Pyatkin I et al.Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1. J Med Chem2012;55: 4764–4775.
  • Webster AD.Pleconaril—an advance in the treatment of enteroviral infection in immuno-compromised patients. J Clin Virol2005;32: 1–6.
  • Arita M, Wakita T, Shimizu H.Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol2008;89: 2518–2530.
  • Zeitlinger MA, Derendorf H, Mouton JW et al.Protein binding: do we ever learn? Antimicrob Agents Chemother2011;55: 3067–3074.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.